Apoptosis, cancer and the p53 tumour suppressor gene

Cancer and Metastasis Reviews

Volumn 14, Issue 2, 1995, Pages 149-161

  Lee, Jonathan M ^a   Bernstein, Alan ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

apoptosis; cancer; cell cycle; DNA damage; p53; tumour suppression

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER; CELL CYCLE; DNA DAMAGE; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMAL; APOPTOSIS; DNA DAMAGE; GENES, P53; HUMAN; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0029038135     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00665797     Document Type: Article

References (113)

1. The tumor suppressor genes
2. Structural aspects of the p53 protein in relation to gene evolution
3. Characterization of a 54 K dalton cellular SV40 tumour antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
4. T antigen is bound to a host protein in SV40-transformed cells
5. Rearrangements of the cellular p53 gene in erythroleukemic cells transformed by Friend virus
6. Suppression of human colorectal carcinoma cell growth by wild-type p53
7. The p53 proto-oncogene can act as a suppressor of transformation
8. Wild-type p53 can inhibit oncogene-mediated focus formation
9. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53
10. Suppression of human colorectal carcinoma cell growth by wild-type p53
11. Genetic mechanisms of tumor suppression by the human p53 gene
12. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein
13. p53: At the crossroads of molecular carcinogenesis and risk assessment
14. p53 mutations in human cancer
15. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis
16. Cellular immortalization by a cDNA clone encoding the transformation associated phosphoprotein p53
17. Participation of the p53 cellular tumour antigen in transformation of normal embryonic cells
18. Cooperation between the gene encoding the p53 tumour antigen and ras in cellular transformation
19. Wild-type p53 but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication
20. Identification of p53 as a sequencespecific DNA-binding protein
21. SV40 T antigen binds specifically to a cellular 53K protein in vitro
22. Characterization of the in vitro interaction between SV40 T antigen and p53: Mapping the p53 binding site
23. Regulation of the human hsp70 promoter by p53
24. Wild-type p53 binds to the TATA-binding protein and represses transcription
25. Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein
26. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
27. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots
28. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein
29. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization
30. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation
31. p53 domains: identification and characterization of two autonomous DNA-binding regions
32. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
33. High resolution structure of the oligomerization domain of p53 by multidimension NMR
34. p53: A glimpse at the puppet behind the shadow play
35. How loops, β sheets, and α helices help us to understand p53
36. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product
37. The MCK enhancer contains a p53 responsive element
38. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
39. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
40. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen
41. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line
42. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
43. Amplification of a gene encoding a p53-associated protein in human sarcomas
44. High incidence of lung, bone, and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene
45. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
46. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
47. Germline transmission of a mutated p53 gene in a cancerprone family with Li-Fraumeni syndrome
48. p53 transgenic mice: accelerated erythroleukemia induction by Friend virus
49. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice
50. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
51. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours
52. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice
53. Gain of function mutations in p53
54. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
55. DNA damage, oncogenesis, and the p53 tumour suppressor
56. Animal cell cycles and their control
57. The role of p34 kinases in the G1 to S-phase transition
58. Mammalian G1 cyclins
59. Rebundant cyclin overexpression and gene amplification in breast cancer cells
60. Amplification of cyclin genes in colorectal carcinomas
61. A novel cyclin encoded by a bc11-linked candidate oncogene
62. Characterization of a candidate bcl-1 gene
63. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy
64. Hartwell LH, Weinert TA: Checkpoints: Controls that ensure the order of cell cycle events. Science 629–634, 1989
65. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae
66. Inhibition of p34cdc2 kinase activity by ectoposide or irradiation as a mechanisms of G2 arrest in Chinese hamster ovary cells
67. Participation of p53 protein in the cellular response to DNA damage
68. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?
69. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways
70. p53 dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
71. The p21 Cdk-interaction protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
72. p21 is a universal inhibitor of cyclin kinases
73. Inhibition of Cdk2 activity in vivo by an associated 20K regulatory subunit
74. WAF1, a potential mediator of p53 tumor suppression
75. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
76. Cyclin-dependent regulation of G1 in mammalian fibroblasts
77. WAF1/CIPI is induced in p53-mediated G1 arrest and apoptosis
78. Wildtype p53 is a cell cycle checkpoint determinant following irradiation
79. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
80. The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro
81. Proliferating cell nuclear antigen is required for DNA excision repair
82. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
83. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
84. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice
85. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis
86. Ataxia-telangiectasia; an inherited disorder of ionizing-radiation sensitivity in man
87. Radiosensitivity in ataxia-telangiectasia: a new explanation
88. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents
89. Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C
90. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair
91. p53 mutations increase resistance to ionizing radiation
92. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes
93. Apoptosis and programmed cell death in immunity
94. An evolutionary perspective on apoptosis
95. Gene induction by γ-irradiation leads to DNA fragmentation in lymphocytes
96. Apoptosis in therapy: crossing the threshold
97. p53 is required for radiation-induced apoptosis in mouse thymocytes
98. Thymocyte apoptosis induced by p53-dependent and independent pathways
99. p53-mediated apoptosis modulates the cytotoxicity of anticancer agents
100. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
101. Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6
102. Growth suppression of Friend-virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin
103. Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning
104. The mammalian ultraviolet response is triggered by activation of src tyrosine kinases
105. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal
106. Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death
107. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2
108. Premature p34cdc2 activation required for apoptosis
109. Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2
110. p53-dependent apoptosis suppresses tumor growth and progression in vivo
111. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
112. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood